Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases

Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie
Paolo LanzettaVision Academy Steering Committee

Abstract

Intravitreal anti-vascular endothelial growth factor (VEGF) therapy is now considered the gold standard for the treatment of various retinal disorders. As therapy has evolved, so too have the treatment regimens employed by physicians in clinical practice; however, visual outcomes observed in the real world have typically not reflected those reported in clinical trials. Possible reasons for this include a lack of consensus on treatment regimens and a lack of clarity about what the aims of treatment should be. The Vision Academy Steering Committee met to discuss the principles of an ideal treatment regimen, using evidence from the literature to substantiate each point. Literature searches were performed using the MEDLINE/PubMed database (cut-off date: March 2016) and restricted to English-language publications. Studies with fewer than ten patients were excluded from this review. The Steering Committee identified the following four key principles for the ideal treatment regimen for anti-VEGF management of retinal diseases: 1. Maximize and maintain visual acuity (VA) benefits for all patients 2. Decide when to treat next, rather than whether to treat now 3. Titrate the treatment intervals to match patients' needs 4. Treat at each m...Continue Reading

References

Nov 15, 2000·The Journals of Gerontology. Series B, Psychological Sciences and Social Sciences·R A MarottoliL F Berkman
Feb 13, 2001·Acta Ophthalmologica Scandinavica·M Lövestam-Adrian, E Agardh
Aug 15, 2002·Proceedings of the National Academy of Sciences of the United States of America·Jocelyn HolashJohn S Rudge
Apr 26, 2003·Investigative Ophthalmology & Visual Science·Susumu IshidaAnthony P Adamis
Jan 28, 2004·Investigative Ophthalmology & Visual Science·Tomohiko UsuiAnthony P Adamis
Jun 1, 2006·American Journal of Public Health·Ellen E FreemanSheila K West
Oct 6, 2006·The New England Journal of Medicine·Philip J RosenfeldUNKNOWN MARINA Study Group
Oct 6, 2006·The New England Journal of Medicine·David M BrownUNKNOWN ANCHOR Study Group
Dec 13, 2006·Archives of Ophthalmology·David B ReinJinan Saaddine
Aug 10, 2007·The New England Journal of Medicine·Marilyn J Manco-JohnsonBruce L Evatt
Nov 15, 2007·Proceedings of the National Academy of Sciences of the United States of America·John S RudgeGeorge D Yancopoulos
Nov 14, 2008·Expert Opinion on Pharmacotherapy·M Amir Ahmadi, Jennifer I Lim
May 30, 2009·American Journal of Ophthalmology·Salomon Y CohenGabriel Quentel
Feb 15, 2012·Ophthalmology·Quan Dong NguyenUNKNOWN RISE and RIDE Research Group
Mar 27, 2012·The British Journal of Ophthalmology·Michael W Stewart
May 5, 2012·Ophthalmology·UNKNOWN Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research GroupFrederick L Ferris
Jun 27, 2012·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Irmela MantelAude Ambresin
Oct 23, 2012·Ophthalmology·Jeffrey S HeierUNKNOWN VIEW 1 and VIEW 2 Study Groups
Oct 23, 2012·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Katharina M DroegeSascha Fauser
Apr 9, 2013·Expert Opinion on Pharmacotherapy·K Bailey FreundRoberto Gallego-Pinazo

❮ Previous
Next ❯

Citations

May 17, 2019·Expert Opinion on Drug Delivery·Francine Behar-Cohen
May 11, 2018·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Justus G GarwegIsabel B Pfister
Aug 24, 2020·The British Journal of Ophthalmology·Ashish SharmaCarl D Regillo
Apr 23, 2020·Eye·Ashish SharmaAnat Loewenstein
Apr 25, 2020·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Jean-François KorobelnikLihteh Wu
Feb 7, 2021·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Nicole EterUNKNOWN PERSEUS Study Group
Feb 22, 2021·Vestnik oftalmologii·R R FayzrakhmanovE O Shatalova
Mar 6, 2021·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Anna BalassoPaolo Caliceti
Aug 9, 2019·Journal of Colloid and Interface Science·Russell MacoonAnuj Chauhan
Sep 28, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Kritika Nayak, Manju Misra
Dec 17, 2020·Archivos de la Sociedad Española de Oftalmología·M M Alberto-PestanoR Abreu-González
Jun 25, 2021·Progress in Retinal and Eye Research·Ursula Schmidt-ErfurthHrvoje Bogunović
Jul 21, 2021·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Masahito OhjiUNKNOWN ALTAIR Investigators
Nov 28, 2019·Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift für Augenheilkunde·Manuel Falcão
Nov 20, 2021·Diabetic Medicine : a Journal of the British Diabetic Association·Tunde PetoUsha Chakravarthy
Dec 30, 2021·Vestnik oftalmologii·M A KovalevskayaE G Kartamyshev

❮ Previous
Next ❯

Software Mentioned

MARINA
COPERNICUS
VIBRANT
VIVID
RIDE
VIEW
AURA
VISTA
BRAVO
RISE

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.